FrancophonIA/ELRC3.0 huggingface dataset:
English: Onset of immunity: 21 days after completion of the primary vaccination scheme Duration of immunity: 12 months after completion of the primary vaccination scheme 4.3 Contraindications
Estonian: Immuunsuse kestus: 12 kuud pärast esmase vaktsineerimiskuuri lõpetamist.
English: Name and address of the manufacturer of the biological active substance(s)
Estonian: Bioloogilis(t)e toimeaine(te) tootja nimi ja aadress
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial label 100 ml and 240 ml
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Viaali etikett 100 ml ja 240 ml
English: A transient increase in rectal temperature, not exceeding 1.2 °C, may occur very commonly during the 24 hours following vaccination.
Estonian: 24 tunni jooksul pärast vaktsineerimist võib väga sageli esineda mööduvat rektaaltemperatuuri tõusu mitte üle 1,2 °C.
English: A transient increase in rectal temperature, not exceeding 0.6 °C, may occur during the 24 hours following administration of a two-fold overdose.
Estonian: 24 tunni jooksul pärast kahekordse üleannuse manustamist võib esineda rektaaltemperatuuri tõusu mitte üle 0,6 °C.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Zulvac 1 Ovis suspension for injection for sheep
Estonian: VETERINAARRAVIMI NIMETUS Zulvac 1 Ovis süstesuspensioon lammastele
English: 4.2 Indications for use, specifying the target species For active immunisation of sheep from 1 and a half months of age for the prevention* of viraemia caused by Bluetongue Virus (BTV), serotype 1.
Estonian: Näidustused, määrates kindlaks vastavad loomaliigid Alates 1 ja poole kuu vanuste lammaste aktiivseks immuniseerimiseks Bluetongue viiruse (BTV) serotüübi 1 põhjustatud vireemia vältimiseks*.
English: For active immunisation of sheep from 1 and a half months of age for the prevention* of viraemia caused by Bluetongue Virus (BTV), serotypes 1.
Estonian: Alates 1 ja poole kuu vanuste lammaste aktiivseks immuniseerimiseks Bluetongue viiruse (BTV) serotüübi 1 põhjustatud vireemia vältimiseks*.
English: PACKAGE SIZE 20 ml (10 doses) 100 ml (50 doses) 240 ml (120 doses)
Estonian: PAKENDI SUURUS(ED) 20 ml (10 annust) 100 ml (50 annust) 240 ml (120 annust)
English: These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 7 days) or of palpable nodules (subcutaneous granuloma, possibly persisting for more than 48 days).
Estonian: Need reaktsioonid väljenduvad enamasti üldise tursena süstekohal (püsivad mitte üle 7 päeva) või palpeeritavate sõlmekestena (subkutaanne granuloom, mis võib püsida üle 48 päeva).
English: PACKAGE SIZE 100 ml (50 doses) 240 ml (120 doses)
Estonian: PAKENDI SUURUS(ED) 100 ml (50 annust) 240 ml (120 annust)
English: A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Estonian: A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(d) JA RAVIMIPARTII VABASTAMISE EEST VASTUTAV(AD) TOOTJA(D)
English: These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 9 days) or of palpable nodules (subcutaneous granuloma, possibly persisting for more than 63 days).
Estonian: Need reaktsioonid väljenduvad enamasti üldise tursena süstekohal (püsivad mitte üle 9 päeva) või palpeeritavate sõlmekestena (subkutaanne granuloom, mis võib püsida üle 63 päeva).
English: Cardboard box with one type II glass vial of either 100 ml (containing 50 doses) or 240 ml (containing 120 doses) with a chlorobutyl rubber stopper and aluminium cap.
Estonian: Pappkarp ühe II tüüpi 100 ml (sisaldab 50 annust) või 240 ml (sisaldab 120 annusti) klaasviaaliga, millel on klorobutüülkummist kork ja alumiiniumkinnitus.
English: Revaccination:
Estonian: Kordusvaktsineerimine
English: Cardboard box with one type I glass vial of 20 ml (containing 10 doses) with a chlorobutyl rubber stopper and aluminium cap.
Estonian: Pappkarp ühe I tüüpi 20 ml (sisaldab 10 annust) klaasviaaliga, millel on klorobutüülkummist kork ja alumiiniumkinnitus.
English: PACKAGE LEAFLET: Zulvac 1 Ovis suspension for injection for sheep
Estonian: PAKENDI INFOLEHT Zulvac 1 Ovis süstesuspensioon lammastele
English: Pregnancy: Can be used during pregnancy.
Estonian: Tiinus Võib kasutada tiinuse ajal.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt http://www.ema.europa.eu/.
English: Excipients: Thiomersal
Estonian: Abiaine: Tiomersaal
English: WITHDRAWAL PERIOD(S) Zero days
Estonian: Keeluaeg (-ajad)
English: None
Estonian: Kõlblikkusaeg
English: STATEMENT OF ACTIVE SUBSTANCES Per dose of 2 ml
Estonian: Viaali etikett 20 ml
English: Adcetris 50 mg Powder for concentrate for solution for infusion
Estonian: 50 mg Infusioonilahuse kontsentraadi pulber
English: Pack size
Estonian: Adcetris
English: The European Commission granted a marketing authorisation valid throughout the European Union for Holoclar on 17 February 2015.
Estonian: Euroopa Komisjon andis Holoclari müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. veebruaril 2015.
English: Other information about Holoclar
Estonian: Muu teave Holoclari kohta
English: A risk management plan has been developed to ensure that Holoclar is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Holoclari võimalikult ohutu kasutamine.
English: Holoclar is intended for a single treatment, although treatment can be repeated if the doctor considers it necessary.
Estonian: Holoclar on ette nähtud ühekordseks raviks, kuigi ravi võib korrata, kui arst peab seda vajalikuks.
English: What measures are being taken to ensure the safe and effective use of Holoclar?
Estonian: Mis meetmed võetakse, et tagada Holoclari ohutu ja efektiivne kasutamine?
English: In the first stage of treatment, a small part of healthy limbal tissue (1−2 mm2 in size) is taken from the patient in hospital and sent to the manufacturer on the same day.
Estonian: Ravi esimeses etapis võetakse patsiendilt haiglas väike tükk (1−2 mm2) korneaallimbuse vigastamata kudet ja saadetakse samal päeval ravimi tootjale.
English: What is Holoclar and what is it used for?
Estonian: Mis on Holoclar ja milleks seda kasutatakse?
English: There were also reductions in patients' symptoms, such as pain and inflammation, and improvements in vision.
Estonian: Patsientidel vähenesid ka muud sümptomid, näiteks valu ja põletik, ning nägemine paranes.
English: The conclusion on the benefit-risk balance of Holoclar is based on results of two retrospective studies (using past medical records), and the company is to provide further data from a prospective study (that records outcomes during the course of the study).
Estonian: Järeldus Holoclari kasulikkuse ja riski tasakaalu kohta põhineb kahe retrospektiivse uuringu (milles kasutati varasemaid terviseandmeid) tulemustel ja ettevõte peab esitama prospektiivse uuringu (milles registreeritakse uuringus saadavaid tulemusi) täiendavad andmed.
English: Educational material will also be provided to patients undergoing treatment.
Estonian: Teabematerjal antakse ka ravitavatele patsientidele.
English: Since Holoclar has been granted a conditional approval, the company that markets Holoclar will provide further data on Holoclar.
Estonian: Et Holoclar kiideti heaks tingimuslikult, esitab Holoclari turustav ettevõte Holoclari kohta täiendavaid andmeid.
English: Why is Holoclar approved?
Estonian: Miks Holoclar heaks kiideti?
English: What information is still awaited for Holoclar?
Estonian: Mis teavet Holoclari kohta veel oodatakse?
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Holoclar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Holoclari kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: As the side effects of Holoclar treatment are generally manageable, the CHMP concluded that Holoclar's benefits outweigh its risks and recommended that it be approved for use in the EU.
Estonian: Et Holoclariga ravi kõrvalnähud on üldiselt ohjatavad, järeldas inimravimite komitee, et Holoclari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The full EPAR and risk management plan summary for Holoclar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Holoclari kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Piirangute ja kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It is not intended to provide practical advice on how to use Holoclar.
Estonian: Hindamisaruandes ei anta Holoclari kasutamise praktilisi nõuandeid.
English: The most common side effect with Holoclar (seen in more than 1 patient in 10) is blepharitis (inflammation of the eye lid).
Estonian: Holoclari kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on blefariit (silmalaupõletik).
English: One year after Holoclar implantation, 75 out of 104 patients studied (72%) were judged to have had successful implants based on the presence of stable corneal surface with no surface defects and little or no ingrown blood vessels (a common feature of limbal stem-cell deficiency).
Estonian: Üks aasta pärast Holoclari siirdamist oli 75 uuritud patsiendil 104st (72%) siirdamine edukas, sest oli tekkinud sarvkesta stabiilne pind, millel puudusid pinnadefektid ja sissekasvanud veresooni (tavaline korneaallimbuse tüvirakkude defitsiidi näht) oli vähe või puudusid need üldse.
English: The company is to provide data on the benefits and risks of Holoclar from a prospective clinical study.
Estonian: Ettevõte esitab Holoclari kasulikkuse ja riskide kohta prospektiivse kliinilise uuringu andmed.
English: What are the risks associated with Holoclar?
Estonian: Mis riskid Holoclariga kaasnevad?
English: Following the surgery, the patient should receive antibiotics and an appropriate antiinflammatory medicine.
Estonian: Pärast operatsiooni tuleb patsiendile anda antibiootikume ja sobivat põletikuvastast ravimit.
English: Next, the cells in the tissue are grown in a laboratory and frozen until the date of surgery is confirmed.
Estonian: Seejärel kasvatatakse koerakke laboris ja need säilitatakse kuni operatsiooni kinnitamise kuupäevani külmutatud kujul.
English: In addition, the company that makes Holoclar will provide healthcare professionals with educational material on the safe use of this treatment, including on the selection and follow-up of patients and on reporting side effects.
Estonian: Lisaks annab Holoclari tootja tervishoiutöötajatele teabematerjali ravimi ohutu kasutamise, sealhulgas patsientide valimise ja järelkontrolli ning kõrvaltoimetest teatamise kohta.
English: How does Holoclar work?
Estonian: Kuidas Holoclar toimib?
English: Holoclar has therefore been given ‘conditional approval'.
Estonian: Holoclari müügiluba anti seetõttu tingimuslikult.
English: Holoclar, comprising the cells and the membrane, is then sent back to the hospital, where it is immediately surgically implanted in the patient's eye.
Estonian: Seejärel saadetakse rakkudest ja membraanist koosnev Holoclar tagasi haiglasse, kus see otsekohe siiratakse patsiendi silma.
English: Holoclar must only be used by an appropriately trained and qualified eye surgeon in a hospital, and must only be given to the patient whose limbal cells were used to manufacture the medicine.
Estonian: Holoclari tohib kasutada ainult nõuetekohase väljaõppega ja pädevusega silmakirurg haiglas ning seda tohib kasutada ainult patsientidel, kelle korneaallimbuse rakkudest toodeti ravim.
English: This is a summary of the European public assessment report (EPAR) for Holoclar.
Estonian: See on ravimi Holoclar Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee noted that that moderate to severe forms of limbal stem-cell deficiency are serious conditions which, if untreated, can lead to severe reduction or complete loss of vision.
Estonian: Komitee märkis, et korneaallimbuse tüvirakkude defitsiidi mõõdukad kuni rasked vormid on rasked haigusseisundid, mille ravimata jätmine võib oluliselt halvendada nägemist või põhjustada täieliku nägemiskaotuse.
English: Because the number of patients with limbal stem-cell deficiency due to burns to the eyes is low, the disease is considered ‘rare', and Holoclar was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 November 2008.
Estonian: Et silma põletusest või söövitusest põhjustatud korneaallimbuse tüvirakkude defitsiidiga patsientide arv on väike ja see haigus esineb harva, nimetati Holoclar 7. novembril 2008 harvikravimiks.
English: Patients with this condition do not have enough limbal stem cells which normally act as a regeneration system, replenishing the outer corneal cells when they get damaged and when they age.
Estonian: Selle seisundiga patsientidel ei ole piisavalt korneaallimbuse tüvirakke, mille abil taastuvad normaalselt sarvkesta välisrakud, kui need kahjustuvad või vananevad.
English: It consists of cells taken from the patient's limbus (at the edge of the cornea) and then grown in a laboratory so that they can be used to repair the damaged corneal surface.
Estonian: See sisaldab rakke, mis on võetud patsiendi korneaallimbusest ja mida on seejärel kasvatatud laboris nii, et nendega saab parandada sarvkesta kahjustatud pinda.
English: For practical information about using Holoclar, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Holoclari kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Holoclar, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Holoclari omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: How is Holoclar used?
Estonian: Kuidas Holoclari kasutatakse?
English: Before Holoclar is used, the damaged corneal surface tissue of the affected eye is removed.
Estonian: Enne Holoclari kasutamist eemaldatakse haige silma sarvkesta pinna kahjustatud kude.
English: For more information about treatment with Holoclar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Holoclariga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Holoclar ex vivo expanded autologous human corneal epithelial cells containing stem cells
Estonian: Holoclar ex vivo kasvatatud autoloogilisi tüvirakke sisaldavad inimese sarvkesta epiteeli rakud
English: The active substance in Holoclar is the patient's own limbal cells, which include cells from the surface of the cornea and limbal stem cells grown in a laboratory.
Estonian: Holoclari toimeaine on patsiendi enda korneaallimbuse rakud, mis sisaldavad sarvkesta pinna rakke ja laboris kasvatatud korneaallimbuse tüvirakke.
English: Holoclar is a stem-cell treatment used in the eye to replace damaged cells on surface (epithelium) of the cornea, the transparent layer in front of the eye covering the iris (the coloured part).
Estonian: Holoclar on tüvirakke sisaldav ravim, mida kasutatakse silmas sarvkesta, st iirist (silma värviline osa) katva läbipaistva kihi kahjustatud pinnarakkude (epiteeli) asendamiseks.
English: What benefits of Holoclar have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Holoclari kasulikkus?
English: Thawed cells are used to make Holoclar by growing them on a membrane made of a protein called fibrin.
Estonian: Sulatatud rakkudest valmistatakse Holoclari, kasvatades neid fibriinmembraanil (teatud valk).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Holoclar treatment was effective in restoring healthy corneal surfaces in patients with moderate or severe limbal stem-cell deficiency caused by burns as well as in improving their symptoms and vision.
Estonian: Inimravimite komitee järeldas, et ravi Holoclariga oli efektiivne silma põletusest või söövitusest põhjustatud mõõduka kuni raske korneaallimbuse tüvirakkude defitsiidiga patsientide sarvkesta terve pinna taastamisel ning sümptomite ja nägemise parandamisel.
English: It is used in adult patients with moderate to severe limbal stem-cell deficiency caused by burns, including chemical burns, to the eyes.
Estonian: Seda kasutatakse täiskasvanud patsientidel, kellel on korneaallimbuse (sarvkesta välisserva) tüvirakkude mõõdukas kuni raske defitsiit, mille on põhjustanud silma põletus või söövitus.
English: Once implanted in the eye, the corneal cells of Holoclar help to replace the corneal surface, while the limbal stem cells serve as a reservoir of new cells that continuously replenish the cornea.
Estonian: Silma siiratud Holoclari sarvkestarakud aitavad asendada sarvkesta pinda ja korneaallimbuse tüvirakkudest tekib uut sarvkestakude ka edaspidi.
English: Holoclar was shown to be effective in restoring a stable corneal surface in patients with moderate or severe limbal stem-cell deficiency caused by burns in a retrospective study using patients' past medical records.
Estonian: Retrospektiivses uuringus, milles kasutati patsientide varasemaid terviseandmeid, osutus Holoclar efektiivseks stabiilse sarvkesta pinna taastamisel silma põletusest või söövitusest põhjustatud mõõduka kuni raske korneaallimbuse tüvirakkude defitsiidiga patsientidel.
English: Antibiotics to prevent eye infection should be given to patients after limbal tissue has been taken from them.
Estonian: Pärast korneaallimbuse koebiopsia võtmist tuleb patsientidele anda silmainfektsiooni ennetamiseks antibiootikume.
English: Holoclar is a type of advanced therapy product called a ‘tissue engineered product'.
Estonian: Holoclar on koetehnoloogiatoodete hulka kuuluv uudne ravim.
English: International Non-proprietary Name (INN): cytarabine
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): tsütarabiin
English: They had concerns with the way the data were analysed.
Estonian: Komitee väljendas ettevaatlikkust andmete analüüsimise viisi suhtes.
English: Cytarabine has been used as an anti-cancer medicine since the 1970s.
Estonian: Tsütarabiini on kasutatud vähiravimina alates 1970. aastatest.
English: Following CHMP opinion, it usually takes around 6 weeks for the European Commission to update the licence.
Estonian: Inimtervishoius kasutatavate ravimite komitee arvamuse järel kulub tavaliselt ligikaudu 6 nädalat, enne kui Euroopa Komisjon loa uuendab.
English: The company presented the results of two studies, involving 164 patients with solid tumour neoplastic meningitis.
Estonian: Ettevõte esitas kahe uuringu tulemused, milles osales 164 patsienti, kellel oli soliidtuumoriga neoplastiline meningiit.
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Estonian: Juhul kui osalete patsiendina kliinilises uuringus või eriloaga kasutamise programmis ja soovite oma ravi kohta lisateavet, võtke palun ühendust teile selle ravi määranud arstiga.
English: The application was at Day 90 when the Company withdrew.
Estonian: Taotluse menetlemine oli kestnud 90 päeva, kui ettevõte selle tagasi võttis.
English: There are no consequences for DepoCyte's use in the indications for which it is already authorised, where the known benefit and risk remain unchanged.
Estonian: Tagasivõtmine ei mõjuta DepoCyte kasutamist näidustuste korral, mille suhtes on müügiluba juba antud ning mille puhul teadaolev kasulikkus ja ohud ei ole muutunud.
English: The studies measured how long it would take before the disease would progress.
Estonian: Uuringutes mõõdeti haiguse progresseerumiseni kulunud aega.
English: The evaluation was finished and the CHMP would have given a negative opinion.
Estonian: Hindamine oli lõpetatud ja inimtervishoius kasutatavate ravimite komitee arvamus oleks olnud negatiivne.
English: On 28 June 2006, SkyePharma PLC officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a new indication for DepoCyte 50 mg suspension for injection, in the intrathecal treatment of solid tumour neoplastic meningitis.
Estonian: 28. juunil 2006 teatas SkyePharma PLC ametlikult inimtervishoius kasutatavate ravimite komiteele oma soovist võtta tagasi ravimile DepoCyte 50 mg süstesuspensioon uue näidustuse, soliidtuumoriga neoplastilise meningiidi intratekaalse ravi lisamise taotlus.
English: The CHMP had concerns that the studies presented by the Company had not sufficiently shown that Depocyte was as effective as, or more effective than intrathecal methotrexate.
Estonian: Inimtervishoius kasutatavate ravimite komitee tundis muret selle üle, et ettevõtte esitatud uuringud ei olnud piisavalt tõestanud, et DepoCyte oleks sama efektiivne või efektiivsem kui intratekaalne metotreksaat.
English: DepoCyte helps control the symptoms of the disease.
Estonian: DepoCyte aitab haigussümptomeid ohjeldada.
English: QUESTIONS AND ANSWERS ON WITHDRAWAL OF APPLICATION FOR A VARIATION OF MARKETING AUTHORISATION for DEPOCYTE
Estonian: TEAVE MÜÜGILOA MUUTMISE TAOTLUSE TAGASIVÕTMISE KOHTA DepoCyte
English: The company has informed the CHMP that the decision has no consequences for patients enrolled in clinical trials or compassionate use programmes.
Estonian: Ettevõte teatas inimtervishoius kasutatavate ravimite komiteele, et sellel otsusel ei ole kliinilistes uuringutes ega eriloaga kasutamise programmides osalevatele patsientidele mitte mingeid tagajärgi.
English: What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with DepoCyte?
Estonian: Millised on taotluse tagasivõtmise tagajärjed DepoCyte kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: The letter from the Company notifying the EMEA of the withdrawal of DepoCyte is available here.
Estonian: Ettevõtte Euroopa Ravimiametitile saadetud kirja DepoCyte taotluse tagasivõtmisest saate lugeda siit.
English: DepoCyte is a suspension for injection that contains 50 mg of the active substance cytarabine.
Estonian: DepoCyte on süstesuspensioon, mis sisaldab toimeainena 50 mg tsütarabiini.
English: DepoCyte contains cytarabine in a special formulation: the active substance is contained in liposomes (small fatty particles) from which it is slowly released.
Estonian: DepoCyte sisaldab tsütarabiini erilise kujul: toimeaine sisaldub liposoomides (väikesed rasvaosakesed), millest see aeglaselt vabaneb.
English: DepoCyte was compared with methotrexate (another anti-cancer medicine), both medicines being administered intrathecally.
Estonian: DepoCytet võrreldi metotreksaadiga (samuti vähiravim); mõlemat ravimit manustatakse intratekaalselt.
English: DepoCyte was to be used in the treatment of solid tumour neoplastic meningitis: this is a disease where cancer cells, originally from a solid tumour (such as lung or breast cancer), spread to the membranes of the nervous system.
Estonian: DepoCytet kavatseti kasutada soliidtuumoriga neoplastilise meningiidi raviks: see on haigus, milles algselt soliidtuumoris (näiteks kopsuvähi või rinnavähi korral) sisalduvad vähirakud levivad närvisüsteemi kelmetesse.
English: DepoCyte was to be injected intrathecally.
Estonian: DepoCytet kavandati süstida intratekaalselt.
English: How is DepoCyte expected to work?
Estonian: Milline on DepoCyte eeldatav toime?